Dr Timothy Price

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone 8222 6000

Map

Selected grants

2013

  • PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer; Price T, Harvey J, Simes R, Zalcberg J, Karapetis C, Tebbutt N; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer; Price T, Harvey J, Tebbutt N, Simes R, Zalcberg J, Karapetis C; Cancer Council New South Wales/Research Project Grants.

2009

  • Short Course Oncology Therapy- A Study of Adjuvant Chemotherapy in Colorecttal Cancer by the CACTUS and OCTO Groups; Haydon A, Price T, Zalcberg J, Walpole E, Yip D, Price T, Howard K, Jefford M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2008

  • Preop chemoradiotherapy&postop chemo with capeciabine&oxaliplatin vs capecitabine alone in locally a; Price T, Harvey J, Tebbutt N, Hruby G, Bydder S, Simes R, Zalcberg J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. [More Information]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. [More Information]
  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]

2012

  • Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. [More Information]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. [More Information]

2011

  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]

2010

  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. [More Information]

2008

  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]

To update your profile click here. For support on your academic profile contact .